Patents by Examiner Hope Robinson
  • Patent number: 9765369
    Abstract: A mutant lysine decarboxylase produced by replacing at least one of the amino acids in SEQ ID NO:4 with another amino acid.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: September 19, 2017
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Daisuke Mochizuki, Tadashi Araki, Akiko Natsuji, Tomomi Sakai, Tomonori Hidesaki
  • Patent number: 9757434
    Abstract: Compositions are provided comprising recombinant variants of the human clotting Factor Xa. Such compositions include a wide variety of isoforms and post-translational modifications of FXa and are useful for treating subjects in need of hemostasis.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: September 12, 2017
    Assignee: PFIZER INC.
    Inventors: Keith A. Johnson, Jason C. Rouse, Penelope Jane Sharpe, Stacey B. Weston, Michael Anthony Jankowski
  • Patent number: 9725739
    Abstract: The present invention relates to a method for preparing D-chiro-inositol from myo-inositol by using a transformed host cell which expresses enzymes such as a myo-inositol transporter, inositol dehydrogenase, and inosose isomerase. According to the method of the present invention, myo-inositol can be converted into D-chiro-inositol at a high yield.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: August 8, 2017
    Assignee: DY NATURAL CO., LTD.
    Inventors: Hyun Koon Myeong, Sang-Hwal Yoon, Hyeon-Seo Lee
  • Patent number: 9708637
    Abstract: A method for producing an L-amino acid is described, for example, L-phenylalanine and L-histidine, by fermentation using a bacterium of the Enterobacteriaceae family, wherein the bacterium has been modified by attaching a DNA fragment able to be transcribed encoding the peptide represented in SEQ ID NO: 2, or a variant thereof, particularly a portion of the ssrA gene, to the 3?-end of gene encoding for the bacterial enzyme, which influences on the L-amino acid biosynthesis, such as chorismate mutase/prephenate dehydrogenase or phosphoglucose isomerase.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: July 18, 2017
    Assignee: AJINOMOTO CO., INC.
    Inventors: Rustem Saidovich Shakulov, Elena Vitalievna Klyachko, Vera Georgievna Doroshenko, Larisa Gotlibovna Airikh
  • Patent number: 9688954
    Abstract: The present invention relates to the enzymatic synthesis of oligosaccharides, particularly, sialylated oligosaccharides comprising the carbohydrate moeities of the gangliosides GM3, GD3, and GT3.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 27, 2017
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventor: Eric Samain
  • Patent number: 9683990
    Abstract: The present invention relates to Angiopoietin-3 (Ang-3) and Angiopoietin-4 (Ang-4). The present invention also relates to methods of modulating an activity of Ang-3 or Ang-4. The present invention further relates to methods of treating cancer, diabetes, and arthritis.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: June 20, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yin Xu, Qin Yu
  • Patent number: 9677062
    Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: June 13, 2017
    Assignee: Halozyme, Inc.
    Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
  • Patent number: 9677061
    Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: June 13, 2017
    Assignee: Halozyme, Inc.
    Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
  • Patent number: 9670512
    Abstract: Compositions and methods for producing hydrocarbons such as aldehydes, alkanes, and alkenes are described herein. Certain hydrocarbons can be used in biofuels.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 6, 2017
    Assignee: REG LIFE SCIENCES, LLC
    Inventors: Andreas W. Schirmer, Mathew A. Rude, Shane Brubaker
  • Patent number: 9663553
    Abstract: The invention is an integrated process for the isolation and purification of plasma derived clotting Factor VIII, clotting Factor IX, albumin and immunoglobulin without the use of ethanol precipitation. The integrated process comprises of sequential chromatography steps of gel filtration, anion exchange and cation exchange chromatographies, followed by viral inactivation and removal steps. The present invention has the advantage of being a mild process that does not denature or aggregate the proteins and provides high yields of several therapeutic grade plasma proteins from a given volume of plasma.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: May 30, 2017
    Assignee: HEMARUS THERAPEUTICS LIMITED
    Inventors: Neelima Vadde, Mitali Samaddar, Ashok Nuvula, Zinia Chakraborty, Swapna Sagar Duggineni, Uma Devi Komath
  • Patent number: 9657328
    Abstract: The present invention relates to a method for modulating thermostability or acid tolerance of a microbe by mutating a nucleic acid molecule encoding a homoserine o-succinyltransferase (MetA) to obtain a nucleic acid molecule encoding a mutant MetA and transforming a microbial cell with the nucleic acid molecule encoding a mutant MetA. The microbe, a bacteria expressing the mutant MetA of the present invention represents a growth rate improved in a vigorous environment such as higher-temperatures and/or lower pH conditions.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: May 23, 2017
    Assignee: Korean Research Institute of Bioscience and Biotechnology
    Inventors: Jae-Gu Pan, Mor Dukhova Elena Anatolievna
  • Patent number: 9649366
    Abstract: Manufacturing and purification processes of complex protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha-1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in plasma, cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain healthy cells and the combination of any of these known or unknown proteins which contain any one of these healthy cells: neutrophil, lymphocyte, eosinophil, basophil, and macrophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: May 16, 2017
    Inventor: Kieu Hoang
  • Patent number: 9650431
    Abstract: The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: May 16, 2017
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Myung-Sam Cho, Sham-Yuen Chan
  • Patent number: 9637528
    Abstract: The invention provides directed evolution methods for improving the folding, solubility and stability (including thermostability) characteristics of polypeptides. In one aspect, the invention provides a method for generating folding and stability-enhanced variants of proteins, including but not limited to fluorescent proteins, chromophoric proteins and enzymes. In another aspect, the invention provides methods for generating thermostable variants of a target protein or polypeptide via an internal destabilization baiting strategy. Internally destabilization a protein of interest is achieved by inserting a heterologous, folding-destabilizing sequence (folding interference domain) within DNA encoding the protein of interest, evolving the protein sequences adjacent to the heterologous insertion to overcome the destabilization (using any number of mutagenesis methods), thereby creating a library of variants. The variants in the library are expressed, and those with enhanced folding characteristics selected.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: May 2, 2017
    Assignee: Los Alamos National Security, LLC
    Inventors: Andrew M. Bradbury, Csaba Kiss, Geoffrey S. Waldo
  • Patent number: 9636384
    Abstract: This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: May 2, 2017
    Assignee: Mayo Foundation For Medical Education and Research
    Inventors: Christopher B. Eckman, Aimee R. Herdt
  • Patent number: 9631211
    Abstract: The present invention relates to a novel bacterial strain designated DD1, which has the ability to produce organic acids, in particular succinic acid (SA), which was originally isolated from bovine rumen, and is capable of utilizing glycerol as a carbon source; and variant strains derived there from retaining said capability; as well as to methods of producing organic acids, in particular succinic acid by making use of said microorganism.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: April 25, 2017
    Assignee: BASF SE
    Inventors: Edzard Scholten, Dirk Dagele, Stephan Haefner, Hartwig Schroder
  • Patent number: 9623146
    Abstract: The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: April 18, 2017
    Assignee: RTI Surgical Technology, Inc.
    Inventors: Francis Vincent Lamberti, Richard Chris Klann, Ronald Stewart Hill
  • Patent number: 9624260
    Abstract: The present invention provides a process for the isolation of one or more proteins) from a protein solution. The process comprising the steps of: a) providing a protein solution comprising one or more specific proteins) and having a preset pH and a preset ionic strength or conductivity, b) applying the protein solution to a packed bed or expanded bed column comprising an adsorbent, and c) obtaining one or more proteins) from the column; wherein the protein solution has been supplemented with an alcohol.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: April 18, 2017
    Assignee: Therapure Biopharma Inc.
    Inventor: Allan Otto Fog Lihme
  • Patent number: 9617523
    Abstract: The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin K reductase complex subunit 1 (VKORC1) and recombinant nucleic acids coding for a vitamin K dependent (VKD) protein, wherein both the recombinant VKORC1 and the recombinant VKD protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant VKD protein expression in a host organism being cultured in suitable systems.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: April 11, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Friedrich Scheiflinger, Ernst Boehm
  • Patent number: 9611503
    Abstract: The objective of this invention is to create a double thyA folA knockout Escherichia coli (E. coli) strain for antifolate screening against DHFR of malaria and other parasites. This strain is used together with a plasmid expressing DHFR-TS from the desired pathogenic organism, which constitutes an anti-DHFR assay against the pathogenic organism of interest. The benefit of this invention is that there is no interference from either host DHFR or trimethoprim, a bacterial DHFR inhibitor. This tool is easy to use and maintain. It provides quick and reliable results as compared with conventional anti-malarial and anti-parasitic assays. This invention should facilitate discovery of new anti-DHFR compounds against malaria and other parasitic diseases.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: April 4, 2017
    Assignee: National Science and Technology Development Agency
    Inventors: Nattida Suwanakitti, Sastra Chaotheing, Yongyuth Yuthavong, Sumalee Kamchonwongpaisan